Scarica l'app Stockscreener
0.3474
5.37%
0.0177
Dopo l'orario di chiusura:
.34
-0.0074
-2.13%
Precedente Chiudi:
$0.3297
Aprire:
$0.3452
Volume 24 ore:
6.91M
Relative Volume:
0.46
Capitalizzazione di mercato:
$81.53M
Reddito:
$48.47M
Utile/perdita netta:
$-170.37M
Rapporto P/E:
-0.4633
EPS:
-0.7499
Flusso di cassa netto:
$-171.35M
1 W Prestazione:
-4.82%
1M Prestazione:
-30.62%
6M Prestazione:
-85.64%
1 anno Prestazione:
-55.91%
Intervallo 1D:
$0.3222
$0.3494
Intervallo di 1 settimana:
$0.32
$0.3814
Portata 52W:
$0.32
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Nome
Gossamer Bio Inc
Settore
Industria
Telefono
(858) 684-1300
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3474 | 77.38M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2025-07-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-05 | Ripresa | Wedbush | Outperform |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-03-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-12-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | JP Morgan | Neutral |
| 2022-09-19 | Iniziato | Wedbush | Outperform |
| 2022-04-18 | Iniziato | Raymond James | Outperform |
| 2022-04-06 | Iniziato | UBS | Buy |
| 2022-01-10 | Aggiornamento | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Ripresa | Piper Sandler | Overweight |
| 2020-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-30 | Iniziato | Berenberg | Buy |
| 2019-03-05 | Iniziato | Barclays | Overweight |
| 2019-03-05 | Iniziato | BofA/Merrill | Buy |
| 2019-03-05 | Iniziato | Evercore ISI | Outperform |
| 2019-03-05 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
GOSS Investor Alert: Gossamer Bio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects - marketscreener.com
Cantor Fitzgerald downgrades Gossamer Bio (GOSS) to neutral - MSN
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral - Yahoo Finance
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit — The Gross Law Firm - Morningstar
Holzer & Holzer, LLC Reminds Investors of June 1, 2026 Lead - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) - The National Law Review
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Stop Loss: Is Gossamer Bio Inc part of any ETFMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - Sahm
Gossamer Bio Lawsuit: Investors Allege Misleading Statements Ahead of Failed PAH Trial - TipRanks
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - lincolnjournal.com
User - The Chronicle-Journal
Investors Seek Lead in Gossamer Bio Securities Fraud Lawsuit - nationaltoday.com
GOSS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Gossamer Bio, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – GOSS - ChartMill
GOSS Investors Invited to Lead Securities Fraud Lawsuit Against Gossamer Bio - nationaltoday.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming DeadlinesGOSS - ChartMill
GOSS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Gossamer Bio, Inc. - ChartMill
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - lincolnjournal.com
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - stocktitan.net
Gossamer Bio, Inc. (4GB.MU) stock price, news, quote and history - Yahoo Finance Australia
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit - The AI Journal
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Gossamer Bio, Inc. (GOSS) Investors – ... - Caledonian Record
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Gossamer Bio, Inc. (GOSS) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - WBOC TV
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP - PR Newswire
Trading Action: Is Gossamer Bio Inc stock a smart retirement pick2026 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
683 Capital Management, LLC Reduces Stake in Gossamer Bio Inc - GuruFocus
Gossamer Bio (GOSS) price target decreased by 53.60% to 4.44 - MSN
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback - insidermonkey.com
Gossamer Bio Receives 'Hold' Rating from Analysts - National Today
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Vanguard reports zero beneficial holdings in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Cantor Fitzgerald downgrades Gossamer Bio (GOSS) - MSN
GOSS (Gossamer Bio) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - PR Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Legal Scrutiny Intensifies for Gossamer Bio Following Clinical Trial Setback () - aktiencheck.de
Options Flow: Is Gossamer Bio Inc a stock for growth or value investorsPortfolio Performance Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
GOSS Technical Analysis | Trend, Signals & Chart Patterns | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio (GOSS) continues downtrend despite impressive revenue - MSN
Setup Watch: Should I set a stop loss on Gossamer Bio IncTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Gossamer Bio Inc Azioni (GOSS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.51%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):